# Bain Capital Life Sciences Investors, LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1703031. Source: https://holderbook.com/funds/1703031-bain-capital-life-sciences-investors-llc/

- Reported value: $1.7B
- Positions: 21
- Weight of the ten largest: 87.9%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| KAILERA THERAPEUTICS INC | [KLRA](https://holderbook.com/stocks/KLRA/) | $497.5M | 22,583,268 | 29.6% | 1 |
| HEARTFLOW INC | [HTFL](https://holderbook.com/stocks/HTFL/) | $247.9M | 8,448,158 | 14.7% | 4 |
| NEWAMSTERDAM PHARMA COMPANY | [NAMS](https://holderbook.com/stocks/NAMS/) | $129.0M | 3,806,566 | 7.7% | 15 |
| SAVARA INC | [SVRA](https://holderbook.com/stocks/SVRA/) | $108.4M | 17,600,621 | 6.4% | 27 |
| ALKERMES PLC | [ALKS](https://holderbook.com/stocks/ALKS/) | $101.5M | 1,937,938 | 6.0% | 2 |
| SOLID BIOSCIENCES INC | [SLDB](https://holderbook.com/stocks/SLDB/) | $98.0M | 9,808,819 | 5.8% | 15 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $92.5M | 2,675,509 | 5.5% | 22 |
| OLEMA PHARMACEUTICALS INC | [OLMA](https://holderbook.com/stocks/OLMA/) | $88.6M | 7,085,249 | 5.3% | 7 |
| HEMAB THERAPEUTICS HLDGS INC | - | $60.6M | 1,650,000 | 3.6% | 1 |
| CABALETTA BIO INC | [CABA](https://holderbook.com/stocks/CABA/) | $53.6M | 17,241,445 | 3.2% | 13 |
| X4 PHARMACEUTICALS INC | [XFOR](https://holderbook.com/stocks/XFOR/) | $37.2M | 7,967,454 | 2.2% | 5 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $35.3M | 362,470 | 2.1% | 10 |
| C4 THERAPEUTICS INC | [CCCC](https://holderbook.com/stocks/CCCC/) | $33.5M | 7,171,910 | 2.0% | 23 |
| KYVERNA THERAPEUTICS INC | [KYTX](https://holderbook.com/stocks/KYTX/) | $25.7M | 2,885,000 | 1.5% | 10 |
| ANNEXON INC | [ANNX](https://holderbook.com/stocks/ANNX/) | $25.3M | 4,437,731 | 1.5% | 24 |
| RAPID MICRO BIOSYSTEMS INC | [RPID](https://holderbook.com/stocks/RPID/) | $14.6M | 8,434,560 | 0.9% | 20 |
| DISC MEDICINE INC | [IRON](https://holderbook.com/stocks/IRON/) | $10.3M | 141,234 | 0.6% | 2 |
| ATEA PHARMACEUTICALS INC | [AVIR](https://holderbook.com/stocks/AVIR/) | $9.7M | 2,075,639 | 0.6% | 23 |
| XILIO THERAPEUTICS INC | [XLO](https://holderbook.com/stocks/XLO/) | $6.4M | 664,021 | 0.4% | 2 |
| UPSTREAM BIO INC | [UPB](https://holderbook.com/stocks/UPB/) | $4.2M | 600,949 | 0.2% | 7 |
| NEWAMSTERDAM PHARMA COMPANY | [NAMSW](https://holderbook.com/stocks/NAMSW/) | $2.1M | 99,999 | 0.1% | 15 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +12.8% | +14.8% | -2.0% | 98% |
| Q1 2026 | -10.8% | -4.6% | -6.1% | 99% |
| Q4 2025 | +39.6% | +2.4% | +37.3% | 100% |
| Q3 2025 | +64.1% | +7.8% | +56.3% | 100% |
| Q2 2025 | +7.8% | +10.5% | -2.6% | 99% |
| Q1 2025 | -22.6% | -4.6% | -18.1% | 100% |
| Q4 2024 | -2.6% | +2.1% | -4.8% | 100% |
| Q3 2024 | +5.3% | +5.4% | -0.1% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $1.7B | 21 |
| Q1 2026 | $1.1B | 20 |
| Q4 2025 | $1.3B | 19 |
| Q3 2025 | $1.5B | 21 |
| Q2 2025 | $799.3M | 23 |
| Q1 2025 | $675.9M | 24 |
| Q4 2024 | $850.1M | 26 |
| Q3 2024 | $961.2M | 24 |
| Q2 2024 | $910.8M | 25 |
| Q1 2024 | $1.2B | 26 |
| Q4 2023 | $1.0B | 27 |
| Q3 2023 | $894.2M | 31 |